BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-745@pharmaconomics
DTSTAMP:20260707T035648Z
DTSTART;VALUE=DATE:20250410
DTEND;VALUE=DATE:20250411
SUMMARY:SGMO Phase 2 — isaralgagene civaparvovec
DESCRIPTION:Phase 2 trial results for isaralgagene civaparvovec in Fabry disease are due Apr 10\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/exhibit-991033026.htm\n\nTrack it: https://www.pharmaconomics.com/e/745
URL:https://www.pharmaconomics.com/e/745
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SGMO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR